NEXUS KNOWLEDGE PUBLICATION
https://nknpub.com/index.php/1

Pharmacology - II
ISBN: 978-81-985724-4-8



DOI 10.5281/zenodo.15399037

Chapter- 4

Pharmacology Of Drugs Acting on The Endocrine System

MS. KOMAL TIKARIYA
Assistant Professor
BM College of Pharmaceutical Education and Research Indore, Pin 452020
Email: komaltikariya77@gmail.com

KOMAL
Assistant professor
Chandigarh College of Pharmcy, Landran, Mohali, Pin code- 140307
Email: komal.5229@cgc.edu.in

MS. NISHA MANDLOI
Assistant Professor
MediCaps University Faculty of Pharmacy, Indore
A.B. Road, Pigdamber, Rau, Indore, Madhya Pradesh
Pin code:- 453331
Email:nishamandloi25@gmail.com

DR G.VENKATA KARTHIK KUMAR REDDY
Assistant professor
The Oxford College of Pharmacy, Hongasandra, Bengaluru, Karnataka, India, 560088
Email: reddyskarthee@gmail.com

DR. M. MARIAPPAN,
Assistant Professor,
Department of Zoology, Government Arts Melur - 625 106, Tamil Nadu.
Email: maripszoo@gmail.com

Unit IV…

PHARMACOLOGY OF DRUGS ACTING ON THE ENDOCRINE SYSTEM

MS. KOMAL TIKARIYA
Assistant Professor
BM College of Pharmaceutical Education and Research Indore, Pin 452020
Email: komaltikariya77@gmail.com

KOMAL
Assistant professor
Chandigarh College of Pharmcy, Landran, Mohali, Pin code- 140307
Email: komal.5229@cgc.edu.in

MS. NISHA MANDLOI
Assistant Professor
MediCaps University Faculty of Pharmacy, Indore
A.B. Road, Pigdamber, Rau, Indore, Madhya Pradesh
Pin code:- 453331
Email:nishamandloi25@gmail.com

DR G.VENKATA KARTHIK KUMAR REDDY
Assistant professor
The Oxford College of Pharmacy, Hongasandra, Bengaluru, Karnataka, India, 560088
Email: reddyskarthee@gmail.com

DR. M. MARIAPPAN,
Assistant Professor,
Department of Zoology, Government Arts College,
Melur - 625 106, Tamil Nadu.
Email: maripszoo@gmail.com

ISBN: 978-81-985724-4-8

4.1 Basic Concepts in Endocrine Pharmacology

One of the primary objectives of endocrine pharmacology involves understanding drug interactions with the endocrine system and thereby effects on hormone secretion, regulation, and action [61]. The endocrine system assists in maintaining homeostasis through the provision of hormones that regulate various physiological processes, such as growth, metabolism, reproduction, and stress response. Medications directed at the endocrine system form a broad scope, including treating conditions like diabetes, thyroid disorders, adrenal insufficiency, and reproductive dysfunction. The study of endocrine pharmacology encompasses basic mechanisms of hormone action and therapeutic interventions designed to modulate these processes for clinical benefit.

Figure 1: Endocrine Pharmacology

Image Source: https://www.medicosisperfectionalis.com/products/p/endocrine-pharmacology-course

❖ Overview of the Endocrine System and Hormone Regulation

The endocrine system is an intricate network of glands and organs that are responsible for the control of homeostasis, metabolism, growth, reproduction, and other essential physiological processes. These glands release their secretions directly into the bloodstream in the form of hormones, which are chemical messengers. Direct release ensures that they reach distant target organs or tissues as soon as possible, where their action is certain for specific effects. The main

ISBN: 978-81-985724-4-8

endocrine glands are the hypothalamus, pituitary gland, thyroid gland, parathyroid glands, adrenal glands, pancreas, ovaries in females, and testes in males. Each one of them specializes in secreting hormones that regulate distinct physiological functions.

Hormones interact with target cells by binding to specific receptors to generate cascades of intracellular signals that will change cellular activity. For example, a peptide hormone produced by the pancreas, called insulin, binds to muscle and liver cells' receptors to regulate glucose uptake and metabolism. Despite their similar functions, hormones fall into several different chemical structures: peptides such as insulin and glucagon; steroids such as cortisol and sex hormones; and amino acid derivatives, such as thyroxine and epinephrine. Such structural diversity allows for the existence of different mechanisms of action and, consequently, varying physiological effects from hormones.

- **Feedback Mechanisms and Hormone Regulation**

The endocrine system relies on feedback mechanisms in regulating hormones. These maintain the levels of hormones within the optimal range. This central regulatory pathway between the nervous and the endocrine systems is known as the hypothalamic-pituitary axis (HPA). In this way, the hypothalamus produces thyrotropin-releasing hormone, which stimulates the anterior pituitary to release thyroid-stimulating hormone [62]. These hormones stimulate the thyroid gland to start producing the thyroid hormones called T3 (triiodothyronine) and T4 (thyroxine). They, when in adequate amount, give negative feedback signals to the hypothalamus and pituitary, thus stopping further secretion of TRH and TSH to prevent overproduction.

Dysregulation in these feedback loops leads to endocrine disorders. Hypothyroidism, which is a condition with low thyroid hormones, can present with fatigue, weight gain, and cold intolerance. Hyperthyroidism is associated with excessive production of thyroid hormones and conditions it with rapid heartbeat, weight loss, irritability, among others, and both conditions call for special diagnosis and pharmacological management to redress hormonal balance.

- **Endocrine Pharmacology: Managing Hormonal Disorders**

Endocrine pharmacology focuses on developing therapeutic interventions to address hormonal imbalances. Treatments are designed to either supplement deficient hormones or inhibit excessive hormonal activity, depending on the underlying condition.

ISBN: 978-81-985724-4-8

1. Hormone Replacement: When the body cannot produce enough hormones, it needs to be supplemented. For example, diabetes mellitus management must involve replacement therapy with insulin as it cannot produce, or lack an adequate response to, its own insulin. Another example is the replacement with synthetic thyroxine (levothyroxine) for hypothyroidism.

2. Actions against Hormonal Activity: Overproduction of hormones is controlled with pharmacological agents that inhibit their synthesis or act to counterbalance their action. Anti-thyroid drugs like methimazole and propylthiouracil can inhibit the synthesis of thyroid hormones, thus treating the hyperthyroidism. Another example is the glucocorticoid inhibitors like ketoconazole used in conditions characterized by excessive production of cortisol, such as Cushing's syndrome.

3. Synthetic Hormone Analogs Synthetic analogs are created to act as mimics or antagonists of the endogenous hormones for their applications in treatment with more precision. A couple of examples: Somatostatin analogs, such as octreotide, prevent the release of growth hormone and have been used in acromegaly. Selective estrogen receptor modulators (SERMs) including tamoxifen inhibit estrogen's actions in hormone-sensitive cancers.

- **The Importance of Hormonal Regulation and Therapeutics**

The fine-tuning of hormones is essential to overall health and well-being. Damage to endocrine function can therefore lead to systemic effects, affecting various organs and physiological processes. Pharmacology in endocrinology is thus not only aimed at restoring imbalances but also enhancing the quality of life in patients suffering from chronic endocrine disorders. With advancements in synthetic analogs and targeted therapies, this field continues to grow, offering treatments with greater efficacy and fewer side effects.

In conclusion, the above complexity of the endocrine system merits a feedback mechanism and accurate control. Pharmacologic therapies targeted on specific hormonal imbalances form the bases for wide endocrinological treatments from diabetes up to thyroid failure with optimal physiological functioning for improved patient outcome.

ISBN: 978-81-985724-4-8

❖ Pharmacodynamics and Pharmacokinetics of Hormones

PD refers to the biological effects of hormones and their mechanisms of action at molecular and cellular levels. Once the hormone binds to its specific receptors, it acts as a ligand to elicit desired physiological responses. The receptors can be located on the cell surface or within the cell, depending on the nature of the hormone. Peptide hormones (such as insulin) cross cell membranes and bind to receptors on the cell surface, initiating signaling cascades involving second messengers such as cAMP or calcium ions. Steroid hormones (like cortisol) and thyroid hormones, as they are lipophilic, diffuse across the cell membrane to combine with intracellular receptors. The hormone-receptor complex then directly affects gene transcription and protein synthesis, so their effect is long-lasting.



Figure 2: Pharmacodynamics and Pharmacokinetics of Hormones

Image Source: https://www.simplilearn.com/what-is-data-collection-article

For instance, insulin binds to its cell surface receptor, a tyrosine kinase, activating intracellular pathways that stimulate glucose uptake, glycogen synthesis, and lipid metabolism. Similarly, cortisol crosses the cell membrane, binds to cytoplasmic glucocorticoid receptors, and regulates genes involved in the suppression of immune responses and metabolism. The potency and efficacy of a hormone are directly related to the sensitivity, binding affinity, and activation duration of the receptor. It is the factors that determine the intensity and duration of physiological response, which is highly relevant in conditions such as insulin resistance in which receptor function is compromised.

ISBN: 978-81-985724-4-8

➢ Pharmacokinetics of Hormones

Pharmacokinetics (PK) refers to the ADME-i.e., absorption, distribution, metabolism, and excretion -of hormones or their synthetic analogs, which determines the therapeutic use. The chemical nature of hormones significantly determines their pharmacokinetic characteristics. Peptide hormones, such as insulin, are sensitive to digestion by gastrointestinal enzymes, and thus cannot be administered orally. Consequently, insulin is administered parenterally via subcutaneous injections, which eliminate the need for accessing the digestive system. Being lipid-soluble, steroid hormones are orally bioavailable since they can easily cross cell membranes and undergo first-pass metabolism in the liver.

The half-life of the hormone-the time for the plasma concentration to fall by half-exerts a direct influence on dosing frequency. For example, natural insulin falls in the category of short half-life drugs; therefore, its administration occurs several times in a day to control blood glucose levels. To mitigate this disadvantage, long-acting analogs of insulin glargine are found, thus introducing more stable blood sugar levels with reduced frequency of dosing. On the other hand, thyroid hormones like levothyroxine have a long half-life that allows for practical once-daily dosing for hypothyroidism treatment [63].

➢ Role of Metabolism in Hormone Clearance

The duration of action and clearance from the body are critical determinants of hormone metabolism. Most hormones are metabolized into inactive forms in the liver biotransformation. The metabolites are excreted via the kidneys. For example, cortisol is subjected to metabolism in the liver into cortisone which is an inactive metabolite, and then excreted in the urine. Synthetic hormone analogs are frequently chemically altered for enhancing the stability of these hormones and extension of their biological activity. For instance, glucocorticoids might be modified to enhance their resistance to metabolic degradation; thus, providing for sustained actions against inflammation.

The pharmacokinetic profiles of hormones and their analogs are critical in determining their onset of action, peak effects, and overall therapeutic utility. For example, rapid-acting insulin analogs are designed for postprandial glucose control while long-acting formulations maintain basal glucose levels.

ISBN: 978-81-985724-4-8

➢ Integration of PD and PK in Endocrine Pharmacology

These components are combined through pharmacodynamics and pharmacokinetics for efficient endocrine drug therapy. The relationship between PD (hormone-receptor interactions) and PK (ADME properties of hormones) characteristics can thus be used by clinicians to develop specific treatments for particular endocrine diseases. Thus, in diabetes mellitus, rapid-acting, short-acting, or long-acting insulins are selected according to an individual's lifestyle, blood sugar patterns, and desired treatment outcome. The dosing of levothyroxine in hypothyroidism is similarly adjusted taking account of the long half-life and the feedback regulation of TSH.

The complexity of hormone physiology and systemic effects underlines the need for precise dosing strategies to avoid adverse effects such as hypoglycemia in diabetes or iatrogenic Cushing's syndrome from excessive corticosteroid use. With synthetic analogues of hormones and delivery methods, the safety, efficacy, and convenience of endocrine therapies continue to advance.

➢ Advancements in Endocrine Therapeutics

The areas of endocrine pharmacology are advancing, largely because of the rapidly progressive fields of molecular biology and pharmacological sciences [64]. In applying such advanced knowledge of hormone-receptor interactions and pharmacokinetics, new therapeutic options are being developed to treat severe conditions, including hormone deficiencies, endocrine tumors, and metabolic disorders. Continuous glucose monitors and pumps, or selective receptor modulators, are just some examples of how progress has been made in bringing personalized and precise endocrine care to patients.

In summary, understanding the pharmacodynamics and pharmacokinetics of hormones is basic to their rational clinical application. A dual approach where therapies would assume not only mimetic roles in hormone function but also compliance with the natural regulatory actions of the body ensures optimality of outcome in the management of endocrine disorders.

4.2 Anterior Pituitary Hormones - Analogues and Their Inhibitors

The anterior pituitary gland is an important endocrine part with the production of several hormones controlling different functions in the body. These hormones include growth hormone (GH), prolactin (PRL), and adrenocorticotropic hormone (ACTH), among others. Dysfunction

ISBN: 978-81-985724-4-8

in their secretion can cause various disorders, which require analogues and inhibitors in the clinical therapy. Understanding the roles of these hormones, and the pharmacologic agents that modify their activity is important for good management of conditions like growth disorders, hyperprolactinemia, and adrenal insufficiency.

- **Role of Growth Hormone (GH)**

Somatotropin, better known by the name growth hormone, is a peptide hormone primarily produced by the anterior pituitary gland. Two critical hypothalamic hormones regulate its secretion: growth hormone-releasing hormone (GHRH), which promotes its release, and somatostatin, an inhibitor. External factors like sleep, exercise, stress, and even nutrient intake influence its pulsatile release. GH is vital for normal growth and metabolic homeostasis, making it a very important hormone throughout life.

GH acts directly through increasing lipolysis, which exposes more fatty acids, and gluconeogenesis, which maintains glucose homeostasis. The bulk of its growth-promoting actions, however, are indirect, mediated by stimulating insulin-like growth factor-1 (IGF-1) production, primarily in the liver. IGF-1 acts on tissues to stimulate protein synthesis, cell multiplication, and chondrocyte growth, all vital for longitudinal bone growth in children.

- **Physiological Role of Growth Hormone**

GH is involved in several metabolic and growth-related processes. This hormone stimulates protein synthesis in muscles and other tissues, bringing about cell growth and repair. This is achieved by mobilizing fatty acids from adipose tissue and encouraging their use for energy. GH lowers the reliance of the body on glucose, thus keeping the blood glucose levels during fasting or stress. This action expresses its role in an energy balance.

GH is vital in children for growth along the linear dimension, especially at puberty. It drives the proliferation of chondrocytes at the epiphyseal growth plates of the long bones, resulting in increased height. In adults, GH still plays a role in body composition by keeping muscle mass, bone density, and metabolic health intact.

- **Growth Hormone Deficiency (GHD)**

Severe clinical consequences can result from GH deficiency. In children, this results in GHD, a condition that leads to short stature, delayed physical development, and growth failure. These

ISBN: 978-81-985724-4-8

children normally have their growth decreased proportionally but may face low self-esteem and social challenges owing to their stature.

In adults, GHD appears differently, since growth has already been achieved. Symptoms include decreasing muscle mass, reduced bone density, which predisposes to osteoporosis, abdominal obesity, and metabolic abnormalities such as dyslipidemia and insulin resistance. A combination of these symptoms leads to reduced physical performance, impaired quality of life, and an increased risk for cardiovascular disorders. The recombinant human GH can improve all of these outcomes, provided the deficiency has been accurately diagnosed.

- **Increased GH: Gigantism and Acromegaly**

Overproduction of GH, resulting from a pituitary adenoma, gives rise to two separate clinical conditions depending upon the timing of hormone overproduction. Excess GH in children leads to gigantism characterized by unatural linear growth during childhood because the epiphyseal growth plates continue to be stimulated beyond their usual closing time. Such individuals can grow excessively tall and in addition experience systemic complications due to excessive tissue growth.

In adults, where the epiphyseal plates have closed or fused, an excess GH leads to acromegaly. It presents with enlargement of bones in the hands, feet, and face, plus soft tissue swelling. Over time, patients may develop complications like hypertension, insulin resistance, and cardiovascular disease, which greatly increase morbidity and mortality.

- **Management of Growth Hormone Disorders at the Clinicians' Level**

The management varies between deficiency and excess cases. GH deficiency is treated with recombinant human GH (rhGH), which is administered as subcutaneous injections. This can help restore normal trajectories of growth in children, and rhGH works in adults to create body composition, enhance bone density, and improve metabolic health.

Treatment for GH excess aims to normalize GH and IGF-1 levels. A variety of treatment options are used, including surgical removal of the pituitary adenoma, radiation therapy, or pharmacological interventions. Drugs that could be used include somatostatin analogs (such as octreotide), dopamine agonists, and GH receptor antagonists (such as pegvisomant) to help control hormone levels and alleviate symptoms.

ISBN: 978-81-985724-4-8

Understanding the intricate balance of GH in the body highlights its importance in both growth and metabolic regulation. Timely diagnosis and tailored treatment of GH-related disorders can significantly improve patient outcomes and quality of life.

❖ Analogues and Inhibitors of Growth Hormone

Therapeutic analogues of growth hormone, such as recombinant human growth hormone (rhGH), are synthetic versions of the natural hormone used to treat growth hormone deficiency (GHD). These analogues are designed to replicate the physiological actions of endogenous GH, including promoting growth in children and regulating metabolism in both children and adults. rhGH therapy is especially useful in children with GHD in whom it can restore normal height by enhancing linear bone growth and muscle mass. In adults, the metabolic imbalances associated with GHD can be corrected, including diminished bone density, altered lipid metabolism, and decreased muscle strength.

rhGH administration must be tailor-made [65]. Dosages are adjusted based on factors like age, body weight, and individual response, with regular monitoring of growth rates in children and IGF-1 levels in both children and adults. This is because monitoring IGF-1, the key mediator of GH activity, ensures effective therapy is being delivered while minimizing the risk for side effects, such as joint pain, edema, or glucose intolerance. It is usually delivered subcutaneously through injections. This is a long-term treatment which gives patients suffering from GHD a good quality of life.

Inhibitors for Excess Growth Hormone

While this can be considered opposite to GHD conditions, excess GH conditions, such as acromegaly, require anti-GH therapies which suppress or otherwise block the activities of GH. Acromegaly is usually the result of an overproduction of GH owing to a pituitary adenoma, which may lead to such symptoms as enlarged hands, feet, and facial bones together with a host of systemic complications such as resistance to insulin and cardiovascular issues. Management therefore requires adequate reduction of GH levels down to normal ranges, which incidentally also regulates IGF-1 production to control tissue overgrowth as well as systemic effects.

Somatostatin analogues, such as octreotide and lanreotide, have become the first-line pharmacological management of GH excess. These drugs have somatostatin-like action: it is an endogenous hormone that suppresses GH release from the pituitary gland. Through binding

ISBN: 978-81-985724-4-8

to somatostatin receptors on pituitary cells, these analogues reduce GH secretion and subsequenly decrease IGF-1 levels. They are delivered either by injections or in long-acting formulations; it leads to increased effects with time, thereby improving patient convenience and compliance.

An alternative therapeutic approach is the use of GH receptor antagonists like pegvisomant. Unlike somatostatin analogues, pegvisomant does not reduce GH secretion but blocks GH receptors in peripheral tissues, thereby preventing GH from exerting its effects. This function inhibits the production of IGF-1, thereby managing the clinical symptoms of acromegaly. Pegvisomant is useful to patients for whom somatostatin analogues do not yield an adequate response, serving as a complementary option in managing GH excess.

Clinical Considerations and Outcomes

Both rhGH for GHD and inhibitors for GH excess need a very carefully considered therapeutic approach with close follow-up to achieve the best outcomes. For patients on rhGH therapy, the primary goal is to support physiological growth and metabolic compensation combined with reduced toxicity. For treatments addressing GH excess, hormone levels are restored to normal, and symptoms are relieved, and long-term complications due to high levels of GH and IGF-1 are decreased.

The development in GH analogues and inhibitors continues to advance with improved treatment efficacy as well as patient quality of life. Tailored therapies, guided by in-depth patient assessments and regular follow-ups, ensure effective management of these hormonal imbalances, paving the way for better health outcomes.

❖ Role of Prolactin (PRL)

Prolactin (PRL) is mainly responsible for lactation, mediating milk production in postpartum women. Unlike other anterior pituitary hormones, the secretion of prolactin is under chiefly inhibitory control by dopamine. Hyperprolactinemia, which refers to elevated prolactin levels, can cause galactorrhea, amenorrhea, and infertility in females and hypogonadism in males. Deficiency of prolactin is an extremely rare condition that causes impaired lactation.

❖ Analogues and Inhibitors of Prolactin

Treatment of hyperprolactinemia consists of dopamine agonists such as cabergoline and bromocriptine. Dopamine agonists cause the inhibition of prolactin secretion by stimulating

ISBN: 978-81-985724-4-8

dopamine receptors. Cabergoline is used more due to its higher efficacy with longer half-life, thus fewer doses. Bromocriptine is effective, though it induces gastrointestinal side effects in most patients.

No prolactin analogue is used in therapy because conditions requiring increased secretion of prolactin are rare. However, dopamine antagonists, such as some antipsychotics, can inadvertently cause an increase in the level of prolactin. Thus, patients who are at risk for hyperprolactinemia should be monitored carefully.

❖ Role of Adrenocorticotropic Hormone (ACTH)

ACTH stimulates the adrenal cortex to produce glucocorticoids, primarily cortisol, as well as mineralocorticoids and adrenal androgens. The release of ACTH is regulated by CRH and has negative feedback by levels of circulating cortisol. Indeed, such core regulation brings major life processes, such as stress responses, immune regulation, and metabolism, under its jurisdiction.

Deficiency of ACTH, secondary adrenal insufficiency, leads to cortisol deficiency, resulting in fatigue, hypotension, and hypoglycemia. Conversely, excessive ACTH secretion, often due to a pituitary tumor (Cushing's disease), causes hypercortisolism manifesting as weight gain, hypertension, and glucose intolerance.

❖ Analogues and Inhibitors of ACTH

ACTH analogues, such as cosyntropin, are used diagnostically to assess adrenal function in patients suspected of adrenal insufficiency. Therapeutically, ACTH analogues are less commonly used, as glucocorticoid replacement (e.g., hydrocortisone or prednisone) is the standard treatment for adrenal insufficiency [66].

In conditions of ACTH excess, such as Cushing's disease, the therapies may be surgery, resection of the pituitary tumor. Pharmacological options are steroidogenesis inhibitors-ketoconazole and metyrapone, reducing cortisol production or pituitary-targeted agents such as pasireotide; it is a somatostatin analogue that inhibits ACTH secretion.

GH, prolactin, and ACTH from the anterior pituitary are crucial hormones in growth, reproduction, and stress response. The analogues of these hormones are used for the treatment of deficiencies, while inhibitors are put to therapeutic use in conditions of hormone excess. In the field of pharmacology, advancement such as selective analogues and receptor antagonists

ISBN: 978-81-985724-4-8

significantly helps in the therapeutic management of pituitary disorders. Careful monitoring and individualized treatment are the keys to optimal outcomes with minimal adverse effects.

4.3 Thyroid Hormones - Analogues and Their Inhibitors

Thyroid hormones, mainly thyroxine (T4) and triiodothyronine (T3), are two of the main regulators of metabolism, growth, and development. Secreted in response to the thyroid-stimulating hormone (TSH) by the thyroid gland, these hormones play an essential role in the maintenance of physiological homeostasis. Diseases of the thyroid include hypothyroidism and hyperthyroidism, for which pharmacological therapy is applied. Analogues replacing deficient hormones and inhibitors of excessive hormone production serve as replacement therapies.



Figure 3: Thyroid Hormones - Analogues and Their Inhibitors

Image Source: https://www.sciencedirect.com/science/article/abs/pii/S0303720717302198

Thyroid Hormones Mechanism of Action

Thyroid hormones play their role in the cell through the complex mechanism of activation of nuclear receptors. The major secretory product of the thyroid gland is thyroxine (T4), which serves as a prohormone and is converted into the more biologically active form, triiodothyronine (T3), in peripheral tissues. This conversion is mediated by enzymes called deiodinases. Once inside target cells, T3 binds to specific thyroid hormone receptors (TRs) located in the cell nucleus. These receptors act as transcription factors that modulate gene

ISBN: 978-81-985724-4-8

expression relevant to different physiological processes. Upon binding with T3, TRs initiate transcriptional activity, which eventually leads to protein synthesis and further effects on metabolism, growth, and organ function.

- ❖ **Physiological Effects of Thyroid Hormones**

- ➢ **Metabolic Regulation**

Thyroid hormones are considered to play an essential role in determining the levels of basal metabolic rate (BMR). They increase energy expenditure, thermogenesis, and oxygen consumption through stimulation of mitochondrial activity and enhanced oxidative phosphorylation [. Their function in stimulating metabolism is vital for maintaining energy balance and adapting to environmental change. For example, thyroid hormones facilitate lipolysis, gluconeogenesis, and glycogenolysis to ensure optimal energy substrate availability during periods of enhanced demand.

Growth and Development

Thyroid hormones are, therefore, critical in the development of the normal brain; otherwise, when there is deficiency, it leads to cretinism, a condition associated with impaired neurocognitive and physical growth. This role is also exhibited in thyroid hormone regulation of growth hormone release and bone remodeling, which makes them essential for proper developmental transitions.

Cardiovascular Effects

The thyroid hormones have a very potent influence on the cardiovascular system, where it increases cardiac output via increased heart rate and contractility of the myocardium and peripheral vasodilation. It does so through the upregulation of β-adrenergic receptors and calcium-handling proteins in the cardiac tissues. These actions enhance the heart's pumping capacity and consequently the tissue perfusion. In instances of dysregulation of thyroid hormones, it leads to cardiac complications that may include tachycardia, arrhythmias, or failure.

Neurological and Musculoskeletal Effects

The CNS is highly sensitive to the levels of thyroid hormones. These hormones maintain neuronal excitability and optimal synaptic function, thereby determining cognitive performance and emotional stability. Thyroid hormones regulate muscle tone, strength, and

ISBN: 978-81-985724-4-8

repair in the musculoskeletal system. A deficiency may result in weakened muscles and sluggish reflexes, while an excess of the hormone may cause tremors and heightened excitability.

❖ Clinical Implications and Therapeutic Interventions

Precise regulation of thyroid hormone levels is essential for proper physiological functioning. Imbalance in this equilibrium may lead to hypothyroidism, an example being Hashimoto's thyroiditis, or hyperthyroidism, an example being Graves' disease. These conditions appear as a range of symptoms that typically vary from one another. Hypothyroidism is characterized by such conditions as low energy, weight gain, and intolerance to cold, whereas hyperthyroidism shows symptoms of weight loss, intolerance to heat, and palpitation.

Targeted pharmacological intervention is aimed to restore hormone levels to normal. In hypothyroidism, appropriate replacement therapy is typically given with levothyroxine, a synthetic form of T4. Treatment for hyperthyroidism can involve antithyroid drugs, for instance methimazole and propylthiouracil, radioactive iodine therapy, or surgical removal of the thyroid gland in the more dangerous forms. Management should be highly customized to meet the individual needs of patients, better understanding of the cause, regular monitoring of the levels of hormones, and individualized treatment plans could ensure proper patient outcomes..

❖ Drugs Used to Treat Hypothyroidism

Hypothyroidism is essentially characterized as a clinical condition resulting from poor production of thyroid hormones, leading to general symptoms that include fatigue, weight gain, intolerance of cold, and bradycardia. The absence of the hormonal balance affects all physical and cognitive functions of the body. The mainstay of hypothyroidism treatment is thyroid hormone replacement therapy, an attempt to achieve normal levels of thyroid hormones in the body to restore metabolic balance and alleviate symptoms. There are several available treatments, and each one has unique mechanisms of action, benefits, and considerations.

Levothyroxine (Synthetic T4): The Gold Standard

Levothyroxine is regarded as the first-line medication for hypothyroidism and is considered the most reliable and effective treatment. Levothyroxine is a synthetic analogue of the main hormone secreted by the thyroid gland, thyroxine (T4). Upon administration, it is converted to

ISBN: 978-81-985724-4-8

triiodothyronine (T3) through the action of certain peripheral tissue enzymes. It acts both as a prohormone and an active hormone. It supports total replacement therapy.

Benefits of Levothyroxine

Levothyroxine has several advantages, thus making it the treatment of choice for most patients. Its long half-life of about 7 days makes dosing once per day very convenient, thereby facilitating much better adherence to therapy. Further, due to its pharmacokinetic profile, constant and stable hormone levels occur if it is administered correctly. The therapy can also be monitored quite easily with serum TSH and free T4 levels, allowing clinicians to maintain highly controlled treatment outcomes.

Monitoring and Adjustments

The effective treatment with levothyroxine necessitates regular check-ups to achieve and maintain euthyroid (normal thyroid hormone) status [67]. The primary marker that monitors treatment adequacy is TSH. Over-treatment can induce iatrogenic hyperthyroidism, caused by symptoms such as palpitations, intolerance to heat, and weight loss. On the other hand, under-treatment can cause persistent hypothyroid symptoms and significantly reduce the quality of life. Dosage adjustments usually occur as changes in physiology may occur, either through pregnancy or weight fluctuations, or with other diseases being present concurrently.

Liothyronine (Synthetic T3): A Quick-Acting Agent

Liothyronine, a synthetic T3 analogue, is used very rarely in certain clinical situations. Its action is more rapid than that of levothyroxine, making it an excellent agent for emergent conditions, such as myxedema coma, a dangerous complication of severe hypothyroidism.

Limitations of Liothyronine

Despite its utility in acute settings, liothyronine is less favored for long-term management of hypothyroidism. Its short half-life of approximately 1 day necessitates multiple daily doses to maintain stable hormone levels, which can be inconvenient for patients. Additionally, the potential for significant fluctuations in T3 levels increases the risk of adverse effects, including palpitations and anxiety. For these reasons, liothyronine is generally reserved for specific cases rather than routine use.

ISBN: 978-81-985724-4-8

Combination Therapy: T4 and T3

Some patients treated with levothyroxine alone still experience only partial symptomatic relief. The TSH and free T4 levels may be within the normal range. For such patients, combination therapy consisting of both T4 (levothyroxine) and T3 (liothyronine) can be prescribed. This helps in mimicking the physiological secretion of the thyroid gland.

Challenge and Controversy

Despite the publication of numerous reports on combination therapy, evidence regarding its benefit remains inconsistent, and it is considered controversial. Some studies argue that there is a subset of patients for whom T3 supplementation will add benefit, while others report virtually no improvement in symptoms. Complexity of dosing and the risk of side effects of T3, such as induction of cardiovascular symptoms, complicate its use and expansion into general practice. Consequently, combination therapy is usually reserved for well-selected patients who do not respond satisfactorily to levothyroxine alone, under close supervision of an endocrinologist.

The treatment of hypothyroidism is individualized for each patient. Most patients are managed with levothyroxine, given that it is the most effective, safest, and easiest to use replacement hormone. Liothyronine and combination therapy may be used in specific situations; however, their use is limited by practical and clinical considerations. No matter what approach to treatment is used, this calls for careful monitoring and dosage adjustments to achieve optimal therapeutic results and enhance quality of life among these patients.

❖ Drugs Used to Treat Hyperthyroidism

Hyperthyroidism is the most common cause of excessive thyroid hormone production, leading to overactive metabolism and a multitude of symptoms. Common clinical manifestations include unintended weight loss, heat intolerance, tachycardia, tremors, and anxiety. This hypermetabolic state disrupts normal physiological processes, significantly impacting quality of life. The key aims of treatment for hyperthyroidism include suppression of excessive production of thyroid hormone, alleviation of symptoms, and removal of underlying causes. Among these aims are Graves' disease and toxic multinodular goiter. There are multiple treatments available, all targeted at individual clinical conditions and patient preferences.

ISBN: 978-81-985724-4-8

Thionamides: Anti-Thyroid Medications

Thionamides are considered the mainstay of pharmacological therapy in hyperthyroidism. These drugs inhibit thyroid hormone synthesis through the inhibition of thyroid peroxidase, the enzyme required for the iodination and coupling of tyrosine residues in thyroglobulin, which is an important step in thyroid hormone production.

Propylthiouracil (PTU)

Propylthiouracil is somewhat unique among the thionamides in that it not only inhibits thyroid hormone synthesis but also prevents the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), the more active form of the hormone. This dual mechanism makes PTU very effective at rapidly reducing T3 levels. PTU is the drug of choice for hyperthyroid patients during the first trimester of pregnancy due to its lower risk of teratogenic effects compared to methimazole [68]. However, its use is limited outside of pregnancy due to a shorter half-life and greater risk of hepatotoxicity.

Methimazole

The thionamide of choice for most patients with hyperthyroidism is methimazole because of its longer half-life, permitting a once-daily dosing regimen and a relatively low incidence of severe side effects compared with PTU. Methimazole is successful in attaining euthyroid status in patients with Graves' disease or toxic multinodular goiter. However, it should not be used during the first trimester of pregnancy because of the association of the drug with teratogenic effects such as aplasia cutis.

Side Effects and Monitoring

Both PTU and methimazole are associated with side effects, including agranulocytosis, a potentially life-threatening decrease in white blood cells, as well as rash and hepatotoxicity. Patients on thionamides need regular monitoring for signs of infection and liver dysfunction, with complete blood counts and liver function tests to be considered during therapy [69].

Radioactive Iodine (I-131) Therapy

Radioiodine therapy is a conclusive form of treatment for hyperthyroidism, especially with the presence of Graves' disease or toxic multinodular goiter. I-131 selectively targets overactive

ISBN: 978-81-985724-4-8

thyroid cells and gives off beta radiation that destroys thyroid tissue and thereby reduces its hormone production.

- **Advantages and disadvantages**

The major benefit of radioiodine treatment is that it is non-invasive and has a high success rate, in that most patients resolve with a single dose. A very high percentage of patients suffer hypothyroidism due to extensive destruction of thyroid tissue and require lifelong replacement therapy with levothyroxine; education of the patient and close monitoring are therefore important for effective management of this consequence.

Beta-Blockers for Symptom Control

Beta-blockers like propranolol are commonly used as an adjuvant treatment in hyperthyroidism to control the effects of enhanced adrenergic activity. These manifestations include tachycardia, shakiness, and agitation, which can be severely debilitating during the acute stages of the disease. Beta-blockers do not decrease the levels of thyroid hormones, but they do alleviate symptoms, thus enhancing the quality of life of the patient during therapy.

Iodides (Potassium Iodide) and Wolff-Chaikoff Effect

Potassium iodide has several distinct uses. These include a preoperative preparation for thyroidectomy or during a thyroid storm, a severe and potentially life-threatening complication of hyperthyroidism. Iodides temporarily suppress thyroid hormone release and synthesis through a self-limiting process termed the Wolff-Chaikoff effect; high concentrations of iodine inhibit thyroid function. However, iodides are not ideal for long-term management because their effects are transient and, once the suppression has passed, can worsen hyperthyroidism.

Surgical Intervention: Thyroidectomy

Patients with severe hyperthyroidism, large goiter, or thyroid cancer, or those who cannot tolerate or have failed other treatments, undergo surgical removal of the thyroid gland, called thyroidectomy. Although thyroidectomy resolves hyperthyroidism definitively, it also poses risks from recurrent laryngeal nerve damage, hypoparathyroidism, and a need for lifelong replacement with thyroid hormone. Proper preoperative preparation with anti-thyroid drugs or iodides is critical to minimize perioperative complications.

ISBN: 978-81-985724-4-8

Comprehensive Care for Thyroid Dysfunction

The management of hyperthyroidism requires a nuanced approach that considers the patient's clinical condition, preferences, and underlying causes of the disease. Thionamides, radioactive iodine therapy, beta-blockers, iodides, and surgery each play specific roles in treatment strategies, with individualized plans ensuring the best outcomes. Alongside these therapies, regular monitoring and patient education are vital to optimize treatment efficacy, prevent complications, and improve long-term quality of life for individuals with thyroid disorders.

4.4 Hormones Regulating Plasma Calcium Level: Parathormone, Calcitonin, and Vitamin D

Calcium is crucial for many of the physiological functions, like bone mineralization, muscle contraction, nerve conduction, and blood coagulation. Plasma calcium is stringently regulated by three main hormones, namely parathormone (PTH), calcitonin, and vitamin D. The effects of these hormones are integrated into physiological control to maintain calcium homeostasis and its availability for necessary biological functions [70].



Figure 4: Parathyroid Hormone

Image Source: https://www.cureus.com/articles/113607-parathyroid-hormone-secretion-and-related-syndromes#!/

ISBN: 978-81-985724-4-8

Role in Calcium Homeostasis

Parathyroid hormone, secreted by parathyroid glands, is the primary regulator of plasma calcium. It plays a key role in calcium homeostasis. The actions of PTH are necessary to ensure that enough calcium is present in the blood to provide for critical functions, such as nerve transmission, muscle contraction, and blood clotting. There are three major sites of PTH action: bones, kidneys, and the gastrointestinal tract.

At bone level, PTH increases the activity of osteoclasts, which increase bone resorption. Osteoclasts dismantle bone tissue and produce calcium and phosphate that end into the blood. Although this helps to raise calcium levels in the plasma, chronic elevation of PTH can lead to bone demineralization and a heightened risk for fractures.

In the kidneys, PTH increases the reabsorption of calcium from renal tubules, and thus reduces the excretion of calcium in urine; it retains calcium inside the blood. At the same time, phosphate reabsorption is also reduced. Consequently, its excretion increases. This increases the ratio of calcium-phosphate in the body due to which its precipitation in the tissues does not occur. It also helps in ensuring proper bone mineralization.

In the gastrointestinal tract, PTH indirectly promotes calcium absorption by stimulating the activation of vitamin D into its active form, calcitriol, in the kidneys. Calcitriol increases the efficiency of calcium absorption from the diet, further contributing to plasma calcium regulation. Together, these mechanisms make PTH an essential hormone for maintaining calcium balance and skeletal health.

Calcitonin

Calcitonin, secreted by the parafollicular cells, also known as C cells of the thyroid gland, is a counter-regulatory hormone to PTH. Its primary role is to decrease plasma calcium levels when they are higher than normal, maintaining calcium homeostasis and preventing hypercalcemia.

In the bones, calcitonin suppresses the activity of the osteoclasts and therefore reduces bone resorption. By limiting the breakdown of bone tissue, calcitonin decreases the release of calcium and phosphate into the bloodstream [71]. This action helps preserve bone density and protect against excessive loss of bone, especially during states of elevated calcium levels.

Calcitonin also increases the urinary excretion of calcium and phosphate in the kidneys. By decreasing the reabsorption of calcium in the renal tubule, calcitonin enhances the removal of

ISBN: 978-81-985724-4-8

excess calcium from the body, leading to its effects as a calcium-lowering hormone. It may be less important than PTH in calcium homeostasis but the actions of calcitonin are very significant when acute increases in calcium levels are occurring as from high levels of calcium following a calcium meal.

Overall, calcitonin offers a safeguarding mechanism against hypercalcemia and helps in the dynamic balance between bone resorption and deposition, ensuring that the skeleton is intact and metabolic stability is maintained.

Vitamin D

Vitamin D, particularly its active form calcitriol, is another critical player in calcium regulation and helps ensure plasma calcium levels are maintained while aiding in healthy bone maintenance. Vitamin D is produced in the skin when exposed to sunlight and proceeds through two hydroxylation steps that involve both liver and kidney actions in becoming calcitriol. Calcitriol enhances the intestinal absorption of dietary calcium, mobilizes calcium from bone, and conserves calcium.

In the gastrointestinal system, calcitriol significantly increases the efficiency of calcium and phosphate absorption in the small intestine. Enhanced absorption promotes adequate amounts of calcium and phosphate for physiological functions in bone mineralization. Dietary calcium absorption is severely impaired with low amounts of calcitriol, which may result in deficiencies and resultant skeletal abnormalities like rickets or osteomalacia.

Calcitriol works synergistically in the bones with PTH to mobilize calcium when levels in plasma are low. It ensures plasma levels of calcium are maintained by stimulating bone resorption under conditions of low calcium. At the same time, it ensures adequate supplies of calcium and phosphate for bone mineralization during periods of bone formation.

In the kidneys, calcitriol increases the reabsorption of calcium in renal tubules and decreases calcium loss in urine. This response cooperates with PTH and effectively conserves calcium, especially during periods of low dietary intake.

Interplay of PTH, Calcitonin, and Vitamin D

The regulation of plasma calcium levels depends upon an effective interplay between PTH, calcitonin, and vitamin D. While PTH and vitamin D act mainly to increase plasma calcium levels during deficiency, calcitonin serves as a kind of counterweight to decrease calcium levels

ISBN: 978-81-985724-4-8

when its levels are excessive. Such balance dynamically ensures that plasma calcium levels are maintained within a very narrow range, critical for neuromuscular function, skeletal integrity, and metabolic stability. Dysregulation of this hormonal interaction leads to clinical conditions like hypocalcemia or hypercalcemia, or bone diseases, making these hormones vital in maintaining calcium homeostasis.

❖ Drugs Targeting Calcium Metabolism

Regulation of calcium metabolism is critical for the upkeep of skeletal health and metabolic balance. Pharmacologic agents that interfere with calcium pathways are important in the management of diseases like osteoporosis, hypercalcemia, hypocalcemia, and other diseases of the bones. These drugs mimic or modulate the actions of critical regulators like parathyroid hormone (PTH), calcitonin, and vitamin D, or act on related pathways.

Parathyroid Hormone Analogues

Parathyroid hormone analogues are anabolic drugs used primarily in the treatment of osteoporosis.

Teriparatide is a synthetic fragment of PTH that is particularly useful for promoting bone formation. It selectively stimulates osteoblast activity more than osteoclast activity, thus increasing density and reducing the risk of fractures. Its application is generally made to patients with severe osteoporosis or those who have not responded to other treatments.

Abaloparatide is a PTH-related protein analogue, which exerts its action by activating the PTH receptor to promote bone formation. Both drugs are administered by subcutaneous injection and are available for short periods to avoid complications resulting from hypercalcemia or increased bone turnover [72].

Calcitonin Analogues

Calcitonin analogues are anti-resorptive drugs used to treat diseases in which the suppression of bone resorption or hypercalcemia needs to be ensured.

Salmon calcitonin, a synthetic version of calcitonin, is particularly effective in conditions like hypercalcemia of malignancy, Paget's disease, and osteoporosis. It reduces osteoclast-mediated bone resorption, helping to stabilize bone density and lower elevated calcium levels.

ISBN: 978-81-985724-4-8

This drug is presented in injectable and nasal spray preparations. Nasal calcitonin has been found to be generally safe and tolerated, but may cause slight irritation or allergic reactions. Long-term therapy is not preferred as their potency decreases and possibly even some risk for carcinogenicity.

Vitamin D and Its Analogues

Vitamin D and its analogues are essential for the mechanism of calcium absorption and bone mineralization.

Cholecalciferol (Vitamin D3) and ergocalciferol (Vitamin D2) are indicated in the treatment of deficiency diseases such as vitamin D deficiency, rickets, and osteomalacia. These forms are inactive precursors that need conversion to their active metabolites.

Calcitriol, the active form of vitamin D, is extremely useful in managing hypocalcemia related to chronic kidney disease or hypoparathyroidism. Calcitriol is absolutely effective in preventing secondary hyperparathyroidism through increased intestinal absorption of calcium and decreased PTH levels.

Synthetic analogues like doxercalciferol and paricalcitol are specifically designed to treat secondary hyperparathyroidism in chronic kidney disease without causing excessive calcium or phosphate elevations.

Bisphosphonates

Bisphosphonates are among the most widely used drugs for conditions involving excessive bone resorption.

Agents like alendronate, risedronate, and zoledronic acid inhibit osteoclast activity, thereby reducing bone breakdown and preserving bone mass. These drugs are highly effective in treating osteoporosis, Paget's disease, and hypercalcemia of malignancy.

Bisphosphonates are usually well tolerated, but they can sometimes cause irritation in the gastrointestinal system, which includes esophagitis, and they also confer the unwanted side effects such as osteonecrosis of the jaw and atypical femoral fractures with long-term usage

ISBN: 978-81-985724-4-8

Calcium-Sensing Receptor Agonists

Cinacalcet is a calcium-sensing receptor agonist, which acts by enhancing the sensitivity of the receptors of the parathyroid glands to circulating calcium. It finds use in treatment and management of primary hyperparathyroidism and secondary hyperparathyroidism in patients suffering from renal failure. The former helps manage hypercalcemia due to reduction in PTH levels and improves balance between calcium and phosphate and the complications related to these.

RANK Ligand Inhibitors

Denosumab is a potent anti-resorptive agent that targets the RANK ligand with a monoclonal antibody. RANK ligand is an important regulator of osteoclast activity, and denosumab's inhibition of this substance significantly reduces bone resorption. Denosumab is commonly used in osteoporosis-affected postmenopausal women at high risk for fractures as well as in the management of bone metastasis and specific cancers. The medication is administered by subcutaneous injection every six months and is a viable alternative to patients who cannot tolerate bisphosphonates.

Calcium Supplements

Calcium supplementation in the form of calcium carbonate and calcium citrate is also essential in the management or prevention of hypocalcemia. They are generally recommended to people whose calcium intake is low, such as postmenopausal women, patients with osteoporosis, or people on drugs that inhibit calcium absorption. While these supplements are essentially nontoxic, high doses may cause hypercalcemia, form kidney stones, or pose cardiovascular risks for sensitive patients.

Phosphate Binders

In patients with chronic kidney disease, high phosphate levels can chelate calcium, disrupting calcium-phosphate balance. Sevelamer and lanthanum carbonate are phosphate binders that decrease intestinal absorption of phosphate indirectly preserving calcium homeostasis. These drugs are especially useful in blocking the vascular calcification and bone disorder caused by hyperphosphatemia.

The pharmacological control of disorders related to calcium is achieved by a wide range of agents acting on PTH, calcitonin, vitamin D, and related pathways. The classes of drugs are

ISBN: 978-81-985724-4-8

also distinct, ranging from stimulating bone formation and inhibiting resorption to regulating calcium and phosphate levels. In addition to these different classes of drugs, clinicians could tailor the therapy to the individual patient's need, thereby being used for conditions like osteoporosis and hypercalcemia, hypocalcemia, and secondary hyperparathyroidism. The ongoing development of these agents strongly emphasizes understanding the intricacies of calcium metabolism and its regulatory mechanisms to attain optimal patient outcomes.

4.5 Insulin, Oral Hypoglycemic Agents, and Glucagon

Diabetes management revolves around regulating blood glucose levels to prevent complications. Insulin, oral hypoglycemic agents, and glucagon play pivotal roles in maintaining glucose homeostasis. Insulin is essential for type 1 diabetes and advanced type 2 diabetes, oral agents are critical for type 2 diabetes management, and glucagon is used in acute settings to counteract severe hypoglycemia [73].



Figure 5: Insulin, Oral Hypoglycemic Agents, and Glucagon

Image Source: https://www.ncbi.nlm.nih.gov/books/NBK279141/

❖ Insulin Therapy and Types of Insulin

Insulin therapy is an important part of the management of diabetes mellitus, especially in type 1 diabetic patients and some subjects with type 2 diabetes who cannot achieve adequate blood

ISBN: 978-81-985724-4-8

glucose control using oral antidiabetic drugs alone. Insulin is a small peptide hormone produced by the pancreas that plays an important role in the regulation of glucose homeostasis in the body. In diabetes, either the body does not produce enough insulin (Type 1 Diabetes) or becomes resistant to its effects (Type 2 Diabetes) [74]. Insulin therapy compensates for these deficiencies by providing the body with the required quantity of insulin necessary to manage the body's blood glucose levels.

Insulin in Type 1 Diabetes

In the case of type 1 diabetes, the immune system destroys all the insulin-producing beta cells in the pancreas, resulting in a complete deficiency of insulin. Therefore, patients with type 1 diabetes need exogenous insulin for maintenance of blood glucose levels. In the absence of insulin, glucose is unable to penetrate the cells, and glucose levels rise in the bloodstream, leading to conditions such as hyperglycemia, which can be acute or chronic, potentially resulting in DKA and damage in blood vessels, nerves, and organs.

Insulin therapy in type 1 DM is usually maintained through injections or an insulin pump. The aim of insulin therapy is to reproduce the body's natural normal secretion of basal and bolus insulin. Basal insulin helps manage blood sugar levels throughout the day and night, while bolus insulin is taken before meals to counteract the rise in blood glucose after eating. Insulin types used include rapid-acting, short-acting, intermediate-acting, and long-acting insulins, which vary in their onset, peak action, and duration of effect.

Insulin in Type 2 Diabetes

In type 2 diabetes, insulin resistance is the primary issue. The body’s cells become less responsive to insulin, and as a result, the pancreas initially produces more insulin to compensate. However, over time, the pancreas may fail to keep up with the demand, leading to relative insulin deficiency. In the early stages of type 2 diabetes, oral agents such as metformin, sulfonylureas, or DPP-4 inhibitors are often sufficient to manage blood glucose levels. However, at more advanced stages of the disease, when the pancreas is unable to secrete sufficient insulin, it becomes necessary for the administration of exogenous insulin to maintain glycemic control.

For patients with type 2 diabetes, medical management usually starts with oral medications alone when they are not able to control their blood sugar or when they are experiencing high levels of hyperglycemia. Similar to type 1 diabetes, type 2 diabetes treatment includes basal

ISBN: 978-81-985724-4-8

and prandial (during meal times) insulin when intravenous therapy alone is not enough to manage the patient's blood glucose in a target range. Basal insulin is often sufficient for some, while others may require both basal and prandial injections.

Mechanism of Action of Insulin

The main action of insulin in the human body is the regulation of the intake of glucose from the tissue, mainly cells of muscle and fat by the cell surface-specific insulin receptors. By binding to these receptors, insulin promotes the translocation of glucose transporters to the cell membrane, thereby helping glucose inside the cell to be used in its energy production or stored for later use.

Thirdly, insulin plays an essential role in the inhibition of gluconeogenesis, which is the glucose production by the liver from other non-carbohydrate precursors such as amino acids and fatty acids. Within physiological conditions, insulin has an inhibitory effect on gluconeogenesis to ensure that the liver does not produce excess glucose [75]. In diabetes, the lack of adequate insulin stimulates gluconeogenesis, contributing to increased levels of blood glucose.

In addition, insulin stimulates glycogen formation in the liver and muscle tissues. Glycogen is the storage form of glucose, which is an energy reserve that can be mobilized to supplement low blood glucose levels, such as during periods of fasting or exercise. With the stimulation of glycogen storage, insulin maintains stable blood glucose levels.

Goals and Adjustments of Insulin Therapy

In insulin therapy, the main objective is to maintain blood glucose levels within the target range in order to avoid both acute complications such as hyperglycemia and hypoglycemia, as well as long-term complications such as cardiovascular disease, neuropathy, nephropathy, and retinopathy. This is often achieved by adjusting doses of insulin with regard to, among other things, blood glucose readings, a schedule of meal times, physical activity levels, and overall health status.

The insulin therapy is therefore mostly accompanied by regular blood glucose monitoring through self-monitoring or the continuous glucose monitoring (CGM) systems in order to enable instant changes in the dose and mode of insulin delivery for both the patients and healthcare providers.

ISBN: 978-81-985724-4-8

In some patients, insulin treatment may be prescribed with adjunctive drugs like GLP-1 receptor agonists, SGLT2 inhibitors, or mealtime insulins to enhance the overall control while minimizing deleterious side effects of insulin therapy, such as weight gain or hypoglycemia.

Insulin is still the foundation of the treatment for type 1 diabetes, but it constitutes a crucial part of type 2 diabetes management, especially when glycemia progression advances and pharmacological therapies require greater intensity. Maintaining blood glucose homeostasis is aided by insulin, which regulates the tissue uptake of glucose, inhibits gluconeogenesis in the liver, and promotes glycogen synthesis. Optimal glycemic control is achieved through proper insulin administration-tailored to the individual's needs and closely monitored-so as to minimize the risk of complications. Nonetheless, with the evolving treatment options for diabetes, insulin therapy remains an effective, though sometimes imperceptible, approach to the management of glucose levels.

❖ Types of Insulin

Insulin therapy is an important part of the management of diabetes mellitus, especially in type 1 diabetic patients and some subjects with type 2 diabetes who cannot achieve adequate blood glucose control using oral antidiabetic drugs alone. Insulin is a small peptide hormone produced by the pancreas that plays an important role in the regulation of glucose homeostasis in the body. In diabetes, either the body does not produce enough insulin (Type 1 Diabetes) or becomes resistant to its effects (Type 2 Diabetes). Insulin therapy compensates for these deficiencies by providing the body with the required quantity of insulin necessary to manage the body's blood glucose levels.

Insulin in Type 1 Diabetes

In the case of type 1 diabetes, the immune system destroys all the insulin-producing beta cells in the pancreas, resulting in a complete deficiency of insulin. Therefore, patients with type 1 diabetes need exogenous insulin for maintenance of blood glucose levels. In the absence of insulin, glucose is unable to penetrate the cells, and glucose levels rise in the bloodstream, leading to conditions such as hyperglycemia, which can be acute or chronic, potentially resulting in DKA and damage in blood vessels, nerves, and organs.

Insulin therapy in type 1 DM is usually maintained through injections or an insulin pump. The aim of insulin therapy is to reproduce the body's natural normal secretion of basal and bolus insulin. Basal insulin helps manage blood sugar levels throughout the day and night, while

ISBN: 978-81-985724-4-8

bolus insulin is taken before meals to counteract the rise in blood glucose after eating. Insulin types used include rapid-acting, short-acting, intermediate-acting, and long-acting insulins, which vary in their onset, peak action, and duration of effect.

Insulin in Type 2 Diabetes

In type 2 diabetes, insulin resistance is the primary issue. The body's cells become less responsive to insulin, and as a result, the pancreas initially produces more insulin to compensate. However, over time, the pancreas may fail to keep up with the demand, leading to relative insulin deficiency. In the early stages of type 2 diabetes, oral agents such as metformin, sulfonylureas, or DPP-4 inhibitors are often sufficient to manage blood glucose levels. However, at more advanced stages of the disease, when the pancreas is unable to secrete sufficient insulin, it becomes necessary for the administration of exogenous insulin to maintain glycemic control.

For patients with type 2 diabetes, medical management usually starts with oral medications alone when they are not able to control their blood sugar or when they are experiencing high levels of hyperglycemia. Similar to type 1 diabetes, type 2 diabetes treatment includes basal and prandial (during meal times) insulin when intravenous therapy alone is not enough to manage the patient's blood glucose in a target range. Basal insulin is often sufficient for some, while others may require both basal and prandial injections.

Mechanism of Action of Insulin

The main action of insulin in the human body is the regulation of the intake of glucose from the tissue, mainly cells of muscle and fat by the cell surface-specific insulin receptors. By binding to these receptors, insulin promotes the translocation of glucose transporters to the cell membrane, thereby helping glucose inside the cell to be used in its energy production or stored for later use.

Thirdly, insulin plays an essential role in the inhibition of gluconeogenesis, which is the glucose production by the liver from other non-carbohydrate precursors such as amino acids and fatty acids. Within physiological conditions, insulin has an inhibitory effect on gluconeogenesis to ensure that the liver does not produce excess glucose. In diabetes, the lack of adequate insulin stimulates gluconeogenesis, contributing to increased levels of blood glucose.

ISBN: 978-81-985724-4-8

In addition, insulin stimulates glycogen formation in the liver and muscle tissues. Glycogen is the storage form of glucose, which is an energy reserve that can be mobilized to supplement low blood glucose levels, such as during periods of fasting or exercise. With the stimulation of glycogen storage, insulin maintains stable blood glucose levels.

Goals and Adjustments of Insulin Therapy

In insulin therapy, the main objective is to maintain blood glucose levels within the target range in order to avoid both acute complications such as hyperglycemia and hypoglycemia, as well as long-term complications such as cardiovascular disease, neuropathy, nephropathy, and retinopathy [76]. This is often achieved by adjusting doses of insulin with regard to, among other things, blood glucose readings, a schedule of meal times, physical activity levels, and overall health status.

The insulin therapy is therefore mostly accompanied by regular blood glucose monitoring through self-monitoring or the continuous glucose monitoring (CGM) systems in order to enable instant changes in the dose and mode of insulin delivery for both the patients and healthcare providers.

In some patients, insulin treatment may be prescribed with adjunctive drugs like GLP-1 receptor agonists, SGLT2 inhibitors, or mealtime insulins to enhance the overall control while minimizing deleterious side effects of insulin therapy, such as weight gain or hypoglycemia.

Insulin is still the foundation of the treatment for type 1 diabetes, but it constitutes a crucial part of type 2 diabetes management, especially when glycemia progression advances and pharmacological therapies require greater intensity. Maintaining blood glucose homeostasis is aided by insulin, which regulates the tissue uptake of glucose, inhibits gluconeogenesis in the liver, and promotes glycogen synthesis. Optimal glycemic control is achieved through proper insulin administration-tailored to the individual's needs and closely monitored-so as to minimize the risk of complications. Nonetheless, with the evolving treatment options for diabetes, insulin therapy remains an effective, though sometimes imperceptible, approach to the management of glucose levels.

❖ Oral Agents for Diabetes Management

Mainstream oral hypoglycemic agents are used in the management of type 2 diabetes. This type of diabetes is caused by a problem in the onset of insulin secretion and also caused by insulin

ISBN: 978-81-985724-4-8

resistance. The basic principle of these drugs involves influencing various aspects of glucose metabolism, such as insulin secretion, insulin sensitivity, and glucose absorption, to influence blood glucose levels. The selection of oral agents depends on the patient's needs, underlying health conditions, and the mechanism of action of the drugs chosen.

1. Biguanides

Metformin stands as a first-line treatment drug for type 2 diabetes and is also the most widely prescribed oral drug. The main action of metformin is its inhibition of hepatic gluconeogenesis, which translates into a reduction in the amount of glucose produced by the liver. This mechanism also enhances the sensitivity of body cells to insulin, making them more responsive to this hormone. This drug has several key benefits, among which is being weight-neutral, a feature that does not contribute to weight gain. Other drugs for diabetes often do. Metformin also has cardiovascular benefits in reducing the risk of heart disease in patients with diabetes. In addition, it has the advantage of not being associated with hypoglycemia when used alone. Nonetheless, it has gastrointestinal disturbances, such as nausea and abdominal discomfort that may limit its use in some patients. One rare but fatal complication is lactic acidosis, which can develop in a person with impaired renal function since the kidneys are primarily in charge of eliminating metformin from the body. As such, a careful observation of kidney function is required.

2. Sulfonylureas

Sulfonylureas, including agents like glipizide, glyburide, and glimepiride operate through the activation of pancreatic beta cells to secrete more insulin. They accomplish this by binding to and closing potassium channels in the beta cells, which creates depolarization and insulin secretion. Sulfonylureas are effective at lowering blood glucose levels, especially when used in the early stages of type 2 diabetes when there is still some insulin secretion. However, there is a high risk of causing hypoglycemia when using these medications, especially when food is missed or the dosing is not appropriately adjusted. They can also lead to weight gain from increased insulin levels, which can be a concern for those trying to achieve both blood glucose control and weight management. While effective, these side effects make them less desirable for patients.

ISBN: 978-81-985724-4-8

3. Meglitinides

Meglitinides, including repaglinide and nateglinide, are similar in mechanism to sulfonylureas because they act by stimulating insulin release from the pancreas but have a shorter duration of action. This makes them particularly useful to manage postprandial glucose rise in blood after meals. Meglitinides help regulate glucose levels by stimulating the release of insulin following eating, though they begin rapidly and have a short duration of action, thus negating much of the risk of hypoglycemia as compared with sulfonylureas. They are usually given just before meals and are taken in a flexible pattern, including dosage. Since they are short-acting, they are much less likely to cause prolonged low blood sugar levels and are preferred for people with erratic eating patterns or those who may not need insulin coverage throughout the day.

4. Thiazolidinediones (TZDs)

Thiazolidinediones, of which pioglitazone and rosiglitazone are examples, constitute a class of drugs that enhance the insulin sensitivity by activating a receptor called PPAR-γ (peroxisome proliferator-activated receptor gamma). This receptor primarily resides in adipose tissue, muscle, and the liver and is activated to enhance glucose uptake, which improves the general responsiveness of cells to insulin. Although TZDs significantly reduce blood glucose concentration, they exert several potential adverse effects. Weight gain is quite common with these medications as they cause fat storage, and edema, a condition where fluid accumulates in one part of the body causing swelling, can occur, which could worsen preexisting heart conditions. In some cases, TZDs have been associated with the increased risk for heart failure, especially in those with pre-existing cardiovascular conditions. Although this risks is posed, pioglitazone has shown benefits in reducing the risk for atherosclerosis and improving lipid profiles in diabetic patients, thus offering extra protection of the cardiovascular system.

5. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

DPP-4 inhibitors (e.g. sitagliptin, saxagliptin, and linagliptin) function by inhibiting an enzyme DPP-4, responsible for the breakdown of incretin hormones. Incretins, like GLP-1 (glucagon-like peptide-1), stimulate the secretion of insulin in response to food and inhibit the release of glucagon into the bloodstream to modulate blood glucose levels. DPP-4 inhibitors prolong the action of incretins, leading to enhanced glucose-dependent insulin release and, consequently, improved blood sugar control [77]. DPP-4 inhibitors are generally well tolerated with little or no risk of hypoglycemia and therefore suitable for patients who tend to have low levels of

ISBN: 978-81-985724-4-8

blood sugar. They are weight-neutral, making them applicable to individuals who should avoid weight gain. However, there is always the possibility of gastrointestinal symptoms such as nausea and pancreatitis in rare cases.

6. Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors

SGLT2 inhibitors are another category of drugs, including empagliflozin, dapagliflozin, and canagliflozin, that reduce glucose reabsorption in the renal tubules. These drugs act via inhibition of the SGLT2 protein in the kidneys, which inhibits glucose reabsorption from the urine back into the bloodstream. This is usually accompanied by urinary glucose excretion as a basis of lowering blood glucose levels. Apart from lowering blood sugar, SGLT2 inhibitors have also been known to be beneficial to the cardiovascular system and are protective of the kidneys, especially in patients with diabetic kidney disease. However, they do have a number of risks including urinary tract infections and the rare risk of DKA. The drugs will also lead to dehydration and hypotension as a result of their diuretic effect.

7. Alpha-Glucosidase Inhibitors

Alpha-glucosidase inhibitors like acarbose and miglitol are drugs that halt the activity of alpha-glucosidase enzymes found in the small intestine to break down carbohydrates into simpler sugars. These will delay the digestion and absorption of carbohydrates, extending the time needed for glucose absorption and resulting in a slower increase in blood glucose following a meal. Alpha-glucosidase inhibitors are used primarily to control postprandial hyperglycemia. However, they are related to side effects including gastrointestinal discomfort of flatulence, diarrhea, and abdominal bloating because undigested carbohydrates are fermented in the colon. They can be uncomforting and its absolute intolerance for some patients with the medication.

8. GLP-1 Receptor Agonists (Injectable)

GLP-1 receptor agonists. These include injectables like liraglutide, exenatide, and semaglutide. They are analogues that mimic the action of the GLP-1 hormone. They increase insulin secretion in a glucose-dependent manner, suppress glucagon release (which prevents the liver from producing too much glucose), and slow gastric emptying, which helps with satiety and weight control. These medications are particularly effective for weight loss and have shown cardiovascular benefits, including reducing the risk of major adverse cardiovascular events. GLP-1 receptor agonists also offer the benefit of low risk of hypoglycemia when used alone. However, their injectable nature may pose a barrier for some patients and they may cause

ISBN: 978-81-985724-4-8

nausea and vomiting, especially at the initiation of treatment. They are increasingly used in addition to other treatments for managing blood sugar levels and weight gain.

Oral hypoglycemic agents are generally a massive range of drugs that can be used for the management of type 2 diabetes, each with its mechanisms, benefits, and possible side effects. Starting from biguanides like metformin, which is actually the cornerstone of type 2 diabetes management, to newer classes like SGLT2 inhibitors and GLP-1 receptor agonists, these drugs work through different mechanisms to achieve regulation of blood glucose. Though each class offers a different set of advantages over others, the choice should be according to the health status, treatment goals, and risk factors of patients. Care and especially a personal treatment plan are necessary to optimize therapy and reduce side effects.

❖ Glucagon and Its Clinical Uses

Glucagon, a peptide hormone produced by pancreatic alpha cells, serves as a physiological antagonist to insulin. It raises blood glucose levels by promoting glycogenolysis and gluconeogenesis in the liver.

➢ Clinical Uses of Glucagon

Glucagon is the hormone of choice in the emergency management of severe hypoglycemia and other serious medical situations. It is an important clinical agent, used to promptly increase blood glucose in patients who suffer from the condition of severe hypoglycemia when glucose from either the oral or intravenous route cannot be administered [78]. In severe cases, it can present in a person with diabetes who has been treated with insulin or specific oral hypoglycemic drugs, and confusion, even loss of consciousness, may result in coma. Glucagon is the emergency treatment that will quickly and efficiently raise the blood glucose levels by stimulating the liver to start releasing stored glucose when blood glucose has reached dangerous lows. The action of glucagon usually occurs within minutes, thus saving a patient's life in case of an emergency.

It is also commercially available in other forms, such as injections and nasal sprays, for convenient usage, especially in case of emergencies. This injection is administered intramuscularly or subcutaneously while the nasal spray is used for patients who can't inject themselves. This makes glucagon an accessible and important tool for both patients with diabetes and caregivers in emergency situations. In the case of severe hypoglycemia, glucagon

ISBN: 978-81-985724-4-8

offers a rapid and effective means to restore blood glucose levels to a safe range, preventing serious complications such as seizures, brain damage, or even death.

Endocrine Diagnostics: Glucagon in Clinical Testing

Beyond its role in emergency treatment, glucagon has clinical application in endocrine diagnosis for the assessment of beta-cell function and in the diagnosis of insulinomas, which are tumors of the pancreas that can lead to overproduction of insulin. In testing for beta-cell function, glucagon is administered to stimulate the release of insulin from the pancreatic beta cells, which can help evaluate the pancreas' ability to produce insulin in response to changes in blood glucose levels. This diagnostic procedure can provide important insights into insulin secretion and help differentiate between different types of diabetes or pancreatic dysfunction.

In the case of insulinoma, glucagon is part of a test for provoking a response in the tumor. Since typical insulinomas involve an abnormally high secretion of insulin, symptoms of hypoglycemia are very common. Through stimulating the tumor, the glucagon test may induce abnormal patterns of insulin production that can be pivotal in the diagnosis and treatment planning.

Reversal of Beta-Blocker Overdose: Cardiovascular Role of Glucagon

Perhaps most importantly, glucagon has a very specific, cardioselective use: the treatment of beta-blocker overdose. Beta-blockers are drugs used to manage cardiovascular conditions such as hypertension, congestive heart failure, and certain forms of arrhythmias. Yet after a significant overdose, beta-blockers administer life-threatening bradycardia (slow heart rate) and hypotension (low blood pressure).

This property of glucagon leads to increased cardiac contractility and enhanced heart rate, therefore helping in neutralizing the toxic effects of beta-blocker overdose. Glucagon counters this through the mechanism of evading the blockade of beta-adrenergic receptors that takes place in a beta-blocker overdose, thus allowing for the better performance of the heart. The ability to activate the heart's action makes glucagon an important agent in the treatment of severe forms of bradycardia and hypotension caused by beta-blocker toxicity. Its cardiostimulatory effects can be a life-saving intervention to help stabilize the patient while further treatments are pursued.

ISBN: 978-81-985724-4-8

Gastrointestinal Relaxation: Glucagon in Radiologic Procedures

Another somewhat lesser-known application of glucagon is in the area of gastrointestinal procedures, specifically those involving radiologic or endoscopic procedures. In these contexts, glucagon is administered to produce GI smooth muscle relaxation, thus facilitating certain diagnostic or therapeutic maneuvers by medical practitioners. As it works to prevent gastric motility, glucagon relaxes the muscles of the stomach and intestines. This is really helpful during procedures like endoscopy, where the physician requires the GI tract to be relatively motionless in order to procure clear images or take biopsies without interference from active bowel movements or muscle contractions. By mildly relaxing the GI muscles, glucagon makes such procedures easier and less invasive, thereby making them more comfortable for the patient.

❖ Side Effects of Glucagon

Despite being an essential adjunct in the management of hypoglycemia and certain other medical emergencies, glucagon is not devoid of side effects. Some of the most common side effects include nausea, vomiting, and a transient elevation of blood sugar levels. The side effects are usually minor and self-limiting, resolving when glucagon is given. In some patients, however, these symptoms may be more severe and must be managed. Allergic reactions to glucagon are infrequent but may also occur, and symptoms may include rash or itching, though severe allergic reactions such as anaphylaxis are very rare. Ideally, the health care provider should be aware of the risk for side effects and monitor patients following glucagon administration, particularly with known allergies or other medical conditions.

In summary, glucagon is an important versatile agent in the management of diabetes as well as in the treatment of a range of medical emergencies. It is a rapid and effective treatment for severe hypoglycemia where the patient immediately gets relief when glucose cannot be given otherwise through an operation that might incur further complications. Glucagon is used not only as an emergency agent, it is also utilized in endocrine diagnostics among which are beta-cell function testing and insulinoma detection. Glucagon also saves lives in reversing beta-blocker overdose and aids in gastrointestinal relaxation for radiological procedures. Glucagon, despite its widespread use, has complications that include nausea, vomiting, and transient hyperglycemia. Despite this, it is highly beneficial in clinical practice, and customized use with insulin and oral hypoglycemic agents is achieved, which ensures optimal glycemic control and effective management of diabetes-related emergencies.

ISBN: 978-81-985724-4-8

4.6 ACTH and Corticosteroids

Adrenocorticotropic hormone (ACTH) and corticosteroids play critical roles in maintaining homeostasis, regulating stress responses, and controlling inflammation and immunity. These hormones are essential in various physiological and pathological processes, making them pivotal in clinical medicine. Synthetic corticosteroids, modeled after naturally occurring hormones, have expanded therapeutic options for numerous conditions.

❖ Role of ACTH and Corticosteroids in the Body

ACTH is a very important hormone secreted by the anterior pituitary gland as it works to control the synthesis of corticosteroids in the adrenal cortex. The production of ACTH is physiologically regulated by the HPA axis, responding to stressors, circadian rhythms, and feedback. ACTH acts as a signal that stimulates the adrenal cortex to produce glucocorticoids (like cortisol), mineralocorticoids (such as aldosterone), and androgens, each of which has distinct roles in the body's metabolic and homeostatic processes [79].

Binding of ACTH to its receptor, melanocortin 2 receptor (MC2R), on the surface of adrenal cells initiates a chain of intracellular events that result in cholesterol conversion to pregnenolone, which is the precursory molecule for corticosteroid synthesis. Pregnenolone is then converted into the various corticosteroids according to the demands of the body under the influence of ACTH. The secretion of ACTH itself is regulated by the release of corticotropin-releasing hormone by the hypothalamus, which forms part of a feedback loop with the adrenal glands to regulate appropriate levels of corticosteroid hormones in circulation. This mechanism ensures that the body maintains its homeostasis under varying conditions, from daily activity cycles to acute stress.

Functions of ACTH

Among the main functions of ACTH is the stimulation of the synthesis of corticosteroids in the adrenal cortex. The interaction between ACTH and its receptor on adrenal cells is necessary for the conversion of cholesterol to pregnenolone. Pregnenolone is the precursor used in the synthesis of corticosteroids; therefore, the interaction is very important for corticosteroid synthesis. These hormones, being involved in metabolism, immune regulation, and response to stressors, have many physiological processes in which their syntheses play key roles.

ISBN: 978-81-985724-4-8

Therefore, with the regulation of their synthesis, the body can respond appropriately to even the most extreme challenges.

The other important function of ACTH is stress response. When the body suffers from stressors like trauma to the body, psychological stress, or infections, the HPA axis is activated. ACTH increases its secretion in response to signals that it gets from the hypothalamus and stimulates the adrenal cortex to secrete cortisol. Cortisol is a very high-powered hormone to mobilize the body's energy stores to respond to the stressor. It includes increasing glucose production, promoting the breakdown of fat for energy, and suppressing processes that are not immediately necessary for survival, like immune responses. In this manner, this adaptive response will ensure that body pools have the energy and resources to handle the stressful situation effectively.

Functions of Corticosteroids

The adrenal cortex synthesizes glucocorticoids, mineralocorticoids, and androgens in response to ACTH. All these corticosteroids have specific functions to facilitate the maintenance of metabolism, immune function, and fluid balance.

1. Glucocorticoids; example-Cortisol Cortisol is the primary glucocorticoid that is very important in the regulation of metabolism. It increases gluconeogenesis, the process by which the liver produces glucose from noncarbohydrate sources, thus raising blood glucose levels during fasting or stress. Cortisol also causes lipolysis, the breakdown of fat storages into fatty acids, which can be an energy source. Cortisol further inhibits protein synthesis, directing amino acids toward glucose production rather than muscle repair. This ensures that glucose is available for critical functions when the body is either under stress or fasting.

Beyond its metabolisms, cortisol has been shown to have tremendous anti-inflammatory and immuosuppressive activities. It is involved in the suppression of pro-inflammatory cytokines and decreases immune cell activity, including T lymphocytes and macrophages, thus serving to modulate the inflammatory response of the body. Cortisol also stabilizes lysosomes, thus preventing the further break down of destructive enzymes from lysosomes when these structures are injured or infected. These results make cortisol indispensable for the prevention of excessive tissue damage during inflammation and immune responses.

Lastly, corticosteroids play a role in stress adaptation. They ensure the mobilization of energy and cardiovascular stability in a state of stress by maintaining the supply of glucose and

ISBN: 978-81-985724-4-8

supporting the vasoconstriction required to preserve blood pressure. Through these mechanisms, it is ensured that the body can respond appropriately to acute stressors without much harm to normal tissues.

2. Mineralocorticoids (e.g. Aldosterone)

Mineralocorticoids with aldosterone being the most notable one is mainly concerned with maintaining electrolyte balance and fluid homeostasis. Aldosterone also has a facilitating effect on the kidneys; it increases sodium reabsorption and potassium excretion in the renal tubules. Both blood pressure and extracellular fluid volume are required to maintain the fluid balance in the body; this is what the mechanism does. Aldosterone increases osmotic pressure in the bloodstream by enhancing sodium retention to increase water and consequently, blood volume, and pressure. This is extremely relevant when the body experiences dehydration or reduction in blood volume, like in hemorrhage or dehydration.

Aldosterone also functions to regulate acid-base balance by encouraging hydrogen ions excretion that have acidic nature, thereby preventing the pH of the blood from becoming excessively acidic due to acidosis.

3. Androgens

In addition, they also produce the androgens dehydroepiandrosterone (DHEA) and androstenedione in much smaller quantities compared to the gonads. These androgens contribute to secondary sexual characteristics, such as pubic and axillary hair growth, especially during puberty. They also have minor metabolic effects, with influences on the metabolism of muscle and bone, and on alterations to their response to stress. While the gonads are the main source of androgens, there is an additional source from the adrenal glands, particularly in females.

In summary, ACTH plays an important role in governing adrenal corticosteroid biosynthesis through the stimulation of glucocorticoids, mineralocorticoids, and androgens that help to maintain metabolic homeostasis, immune function, fluid balance, and stress adaptation. Cortisol, the primary glucocorticoid, plays essential roles in energy mobilization and inflammation suppression during stress, while aldosterone regulates electrolyte balance and blood pressure. Though produced in small amounts, androgens also contribute to secondary sexual characteristics and metabolic regulation. Together, under the control of ACTH, these corticosteroids are able to allow the body to behave dynamically in response to environmental

ISBN: 978-81-985724-4-8

or physiological alterations, ensuring stability and adaptation in times of stress or altered metabolic need.

❖ Synthetic Corticosteroids in Clinical Use

Synthetic corticosteroids are semisynthetic modifications of natural corticosteroids engineered in laboratories for increased potency and receptor affinity in addition to selective alterations of metabolic profiles for specific therapeutic purposes. Since synthetic corticosteroids can either mimic or modulate the actions of endogenous hormones, such as corticosteroids, they mimic or alter the effects of endogenous hormones in several medical conditions. Synthetic corticosteroids have very wide ranges of therapeutic uses, and they are indispensable in the management of inflammatory, autoimmune, and endocrine conditions. They control inflammation, modulate immune responses, and correct deficiencies in corticosteroid production, making them essential in modern medical practice.

❖ Popular Synthetic Corticosteroids

Glucocorticoids:

Hydrocortisone: Hydrocortisone is a synthetic glucocorticoid, structurally similar to cortisol, and its application is the first-line replacement therapy in adrenal insufficiency. It is the most natural form of synthetic glucocorticoid and prevents the normal functions of adrenal glands from being disrupted in cases when it cannot produce enough amounts of cortisol due to conditions like Addison's disease or congenital adrenal hyperplasia. Hydrocortisone has both glucocorticoid and mineralocorticoid effects, although it is less potent than other synthetic corticosteroids in terms of anti-inflammatory properties [80].

Prednisolone and Prednisone: These are intermediate-acting glucocorticoids that are commonly used in the treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Prednisolone is an active form of prednisone, which is converted to prednisolone in the liver. They are preferred because they have middle potency with effective anti-inflammatory and immunosuppressive action. These corticosteroids control inflammation symptoms by inhibiting the action of immune cells and preventing pro-inflammatory cytokines.

Dexamethasone: Dexamethasone is a very potent long-acting glucocorticoid with minimal mineralocorticoid activity and is quite suitable for use in patients who require significant anti-

ISBN: 978-81-985724-4-8

inflammatory effects without much fluid retention. It is commonly used in the treatment of cerebral edema, septic shock, and as an antiemetic in chemotherapy. Because of its efficacy in managing inflammation in conditions as severe as brain tumor or injury, it finds a position as part and parcel of the clinical arsenal for dealing with serious conditions that call for aggressive anti-inflammatory therapy.

Betamethasone: Betamethasone is used in antenatal therapy to promote fetal lung maturation in preterm labor. This synthetic glucocorticoid has been proven to significantly improve outcomes in preterm infants by accelerating the development of the lungs and reducing the risk of respiratory distress syndrome. It is also used to treat various inflammatory conditions, including allergic reactions and autoimmune diseases.

Mineralocorticoids:

Fludrocortisone: Fludrocortisone is a synthetic aldosterone analog, whose sodium retaining activity is the most potent of all synthetic steroid compounds. Its primary application is in the treatment of adrenal insufficiency, especially in Addison's disease, where both glucocorticoids and mineralocorticoids are secreted insufficiently by the adrenal glands. Through raising renal sodium retention, fludrocortisone promotes the maintenance of electrolyte balance and blood pressure, the latter essential for any Addison's disease patient.

- **Medical Uses of Synthetic Corticosteroids**

Synthetic corticosteroids have various medical applications in the area of replacement therapy, anti-inflammatory and immunosuppressive therapy:

Replacement Therapy: Synthetic corticosteroids, such as hydrocortisone are used as replacement for deficient hormones in the body of patients with adrenal insufficiency or other disorders, such as congenital adrenal hyperplasia, where the adrenal glands fail to produce adequate corticosteroids. In these instances, synthetic corticosteroids replace normal corticosteroid levels in the body, allowing it to remain functional for the metabolic needs of maintaining bodily stress and blood sugar, electrolyte balance, and inflammation.

Anti-Inflammatory and Immunosuppressive Therapy: Synthetic corticosteroids are so fundamental in treating a broad spectrum of inflammatory disorders including asthma, allergic diseases, inflammatory bowel diseases, and autoimmune disorders like rheumatoid arthritis and systemic lupus erythematosus. By inhibiting the immune response and blocking inflammation,

ISBN: 978-81-985724-4-8

corticosteroids help to minimize symptoms such as pain, swelling, and tissue injury. They are crucial in the post-transplant immunosuppression, where the drugs suppress the body's immune response against the transplanted tissue to prevent organ rejection.

Management of Autoimmune Disorders. Synthetic corticosteroids are a mainstay in managing autoimmune conditions such as multiple sclerosis and vasculitis. In these conditions, the immune system mistakenly attacks the body's tissues. Reducing the activity of the immune system with corticosteroids alleviates the condition and would prevent such further damage to organs and tissues.

Oncology: Dexamethasone is often prescribed in oncology to minimize tumor-associated inflammation and control chemotherapy-induced nausea and vomiting. Inflammation in the area surrounding tumors can be reduced, and cytokines causing these worsening symptoms of cancer are also decreased, through high-dose corticosteroids. They are further used in the management of brain tumors to decrease swelling and pressure within the cranium.

Shock and Critical Illness: High dose corticosteroids are sometimes used in septic shock and in severe allergic reactions. In such severe conditions, the drug stabilizes the cardiovascular system, reduces inflammation, and prevents further tissue damage. Corticosteroids are also used in adrenal crisis, which can be present in patients with Addison's disease or adrenal insufficiency, particularly at times of major illness or stress .

Side Effects of Corticosteroids

While synthetic corticosteroids offer immense therapeutic benefits, prolonged or inappropriate use can lead to significant adverse effects. The potential side effects are particularly concerning in patients receiving long-term treatment.

Endocrine Effects: Therefore, chronic corticosteroid use suppresses the HPA axis, where the body's natural production of cortisol is decreased. The results are associated with hyperglycemia and the manifestation of Cushingoid features, which involve obese stature, round face, and adiposity, especially in the abdominal area.

Musculoskeletal Effects: Long-term use of corticosteroids is also associated with osteoporosis, increased risk of bone fractures, and myopathy. Children also suffer from growth suppression caused by the effects of steroids on growth hormones and bone metabolism.

ISBN: 978-81-985724-4-8

Cardiovascular Effects: Corticosteroids can cause hypertension and fluid retention. Both could potentially worsen cardiac or vascular disease. Most of these effects result from the mineralocorticoid activity of synthetic corticosteroids, which stimulate sodium retention and increase blood pressure.

Immune Effects: While corticosteroids are used to suppress the immune response in cases of inflammation and autoimmune diseases, they also increase susceptibility to infections, including opportunistic infections like fungal or viral infections, due to their immunosuppressive effects.

Psychiatric Effects: Corticosteroids can cause mood changes, insomnia, and, in severe cases, psychosis. The mental health impact of corticosteroids is a significant concern, especially in patients who are on long-term therapy.

ACTH and synthetic corticosteroids take a central role within the context of the body's response to stress, metabolic regulation, and immune modulation. Synthetic corticosteroids have revolutionized the treatment of numerous conditions from endocrine disorders to inflammation and autoimmune diseases. Their possibilities for use in therapy are immense, but so is their danger, requiring careful monitoring and individually developed treatment regimens. While corticosteroids are extremely effective, it is the responsibility of clinicians to weigh the therapeutic benefits against the risks of the medication and ensure that patients receive appropriate care while minimizing adverse outcomes. This approach underscores the need for careful management and vigilant monitoring during corticosteroid therapy.

ISBN: 978-81-985724-4-8

REFERENCES

1. Javed, T., & Shattat, G. F. (2007). Cardiovascular pharmacology. In *Advanced Drug Formulation Design to Optimize Therapeutic Outcomes* (pp. 379-428). CRC Press.
2. Procaccini, D. E., Sawyer, J. E., & Watt, K. M. (2019). Pharmacology of Cardiovascular drugs. In *Critical Heart Disease in Infants and Children* (pp. 192-212). Elsevier.
3. Atzeni, F., Turiel, M., Caporali, R., Cavagna, L., Tomasoni, L., Sitia, S., & Sarzi-Puttini, P. (2010). The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmunity reviews, 9(12), 835-839.
4. Dhein, S. (2004). Pharmacology of gap junctions in the cardiovascular system. *Cardiovascular research*, *62*(2), 287-298.
5. Pugsley, M. K. (2002). The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system. *Pharmacology & therapeutics*, *93*(1), 51-75.
6. Trifiro, G., & Spina, E. (2011). Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. *Current drug metabolism*, *12*(7), 611-620.
7. Ross, J. J. (2001). A systematic approach to cardiovascular pharmacology. *Continuing Education in Anaesthesia, Critical Care & Pain*, *1*(1), 8-11.
8. Bhattacharya, M., & Alper, S. L. (2011). Pharmacology of. *Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy*, 332.
9. Li, P., Fu, Y., Ru, J., Huang, C., Du, J., Zheng, C., ... & Wang, Y. (2014). Insights from systems pharmacology into cardiovascular drug discovery and therapy. *BMC systems biology*, *8*, 1-13.
10. Grosser, T., Ricciotti, E., & FitzGerald, G. A. (2017). The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. *Trends in pharmacological sciences*, *38*(8), 733-748.
11. Rongen, G. A., Floras, J. S., Lenders, J. W., Thien, T., & Smits, P. (1997). Cardiovascular pharmacology of purines. *Clinical Science*, *92*(1), 13-24.
12. Hiley, C. R., & Ford, W. R. (2004). Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. *Biological Reviews*, *79*(1), 187-205.
13. Dhein, S. (1998). Gap junction channels in the cardiovascular system: pharmacological and physiological modulation. *Trends in pharmacological sciences*, *19*(6), 229-241.

ISBN: 978-81-985724-4-8

14. Finkel, R., Clark, M. A., & Cubeddu, L. X. (Eds.). (2009). *Pharmacology*. Lippincott Williams & Wilkins.
15. Zanesco, A., & Antunes, E. (2007). Effects of exercise training on the cardiovascular system: pharmacological approaches. *Pharmacology & therapeutics*, *114*(3), 307-317.
16. Cross, M. J., Berridge, B. R., Clements, P. J. M., Cove-Smith, L., Force, T. L., Hoffmann, P., ... & Park, B. K. (2015). Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. *British Journal of Pharmacology*, *172*(4), 957-974.
17. Shryock, J. C., & Belardinelli, L. (1997). Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. *The American journal of cardiology*, *79*(12), 2-10.
18. Huang, C. L. H., Wu, L., Jeevaratnam, K., & Lei, M. (2020). Update on antiarrhythmic drug pharmacology. *Journal of cardiovascular electrophysiology*, *31*(2), 579-592.
19. FitzGerald, G. A. (2002). Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. *The American journal of cardiology*, *89*(6), 26-32.
20. Reidenberg, M. M. (2011). Drug discontinuation effects are part of the pharmacology of a drug. *Journal of Pharmacology and Experimental Therapeutics*, *339*(2), 324-328.
21. Mitchell, J. A., Kirkby, N. S., Ahmetaj-Shala, B., Armstrong, P. C., Crescente, M., Ferreira, P., ... & Warner, T. D. (2021). Cyclooxygenases and the cardiovascular system. *Pharmacology & therapeutics*, *217*, 107624.
22. Katz, A. M., Hager, W. D., Messineo, F. C., & Pappano, A. J. (1984). Cellular actions and pharmacology of the calcium channel blocking drugs. *The American journal of medicine*, *77*(2), 2-10.
23. Pepper, G. A. (1999). Pharmacology of antihypertensive drugs. *Journal of Obstetric, Gynecologic, & Neonatal Nursing*, *28*(6), 649-659.
24. Ram, C. V. S., & Fenves, A. (2002). Clinical pharmacology of antihypertensive drugs. *Cardiology clinics*, *20*(2), 265-280.
25. Brodde, O. E. (1990). Physiology and pharmacology of cardiovascular catecholamine receptors: implications for treatment of chronic heart failure. *American Heart Journal*, *120*(6), 1565-1572.
26. Kleinz, M. J., & Spence, I. (2008). The pharmacology of the autonomic nervous system. *Small animal clinical pharmacology. Saunders Elsevier, USA, Philadelphia*, 59-82.

ISBN: 978-81-985724-4-8

27. Docherty, J. R., & Alsufyani, H. A. (2021). Pharmacology of drugs used as stimulants. *The Journal of Clinical Pharmacology*, *61*, S53-S69.
28. Petraina, A., Nogales, C., Krahn, T., Mucke, H., Lüscher, T. F., Fischmeister, R., ... & Schmidt, H. H. (2022). Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology. *Cardiovascular research*, *118*(9), 2085-2102.
29. Rosano, G. M., Lewis, B., Agewall, S., Wassmann, S., Vitale, C., Schmidt, H., ... & Tamargo, J. (2015). Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC. *European heart journal*, *36*(40), 2677-2680.
30. Reynolds, E. W., & Bada, H. S. (2003). Pharmacology of drugs of abuse. *Obstetrics and Gynecology Clinics*, *30*(3), 501-522.
31. Jozsef Szentmiklosi, A., Szentandrássy, N., Hegyi, B., Horváth, B., Magyar, J., Bányász, T., & P Nanasi, P. (2015). Chemistry, physiology, and pharmacology of β-adrenergic mechanisms in the heart. Why are β-blocker antiarrhythmics superior?. *Current pharmaceutical design*, *21*(8), 1030-1041.
32. Yu, G., Luo, Z., Zhou, Y., Zhang, L., Wu, Y., Ding, L., & Shi, Y. (2019). Uncovering the pharmacological mechanism of Carthamus tinctorius L. on cardiovascular disease by a systems pharmacology approach. *Biomedicine & pharmacotherapy*, *117*, 109094.
33. Waller, D. G., & Hitchings, A. W. (2021). *Medical Pharmacology and Therapeutics E-Book: Medical Pharmacology and Therapeutics E-Book*. Elsevier Health Sciences.
34. Smith, D. H. (2001). Pharmacology of cardiovascular chronotherapeutic agents. *American journal of hypertension*, *14*(S6), 296S-301S.
35. Katzung, B. G., Masters, S. B., & Trevor, A. J. (Eds.). (2004). Basic & clinical pharmacology.
36. Tripathi, K. D. (2020). *Essentials of pharmacology for dentistry*. Jaypee Brothers Medical Publishers.
37. Lokhandwala, M. F., & Hegde, S. S. (1991). Cardiovascular pharmacology of adrenergic and dopaminergic receptors: therapeutic significance in congestive heart failure. *The American journal of medicine*, *90*(5), S2-S9.
38. Johnson, D. A., & Hricik, J. G. (1993). The pharmacology of α-adrenergic decongestants. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, *13*(6P2), 110S-115S.

ISBN: 978-81-985724-4-8

39. Wollam, G. L., Gifford, R. W., & Tarazi, R. C. (1977). Antihypertensive drugs: Clinical pharmacology and therapeutic use. *Drugs*, *14*, 420-460.
40. Van Zwieten, P. A. (1988). Antihypertensive drugs interacting with α-and β-adrenoceptors: a review of basic pharmacology. *Drugs*, *35*(Suppl 6), 6-19.
41. Schindler, C. W., Tella, S. R., Erzouki, H. K., & Goldberg, S. R. (1995). Pharmacological mechanisms in cocaine's cardiovascular effects. *Drug and alcohol dependence*, *37*(3), 183-191.
42. Prys-Roberts, C. (1995). Cardiovascular pharmacology: Editorial Review. *Current Opinion in Anesthesiology*, *8*(1), 69-74.
43. Cheng, C. K., Luo, J. Y., Lau, C. W., Chen, Z. Y., Tian, X. Y., & Huang, Y. (2020). Pharmacological basis and new insights of resveratrol action in the cardiovascular system. *British Journal of Pharmacology*, *177*(6), 1258-1277.
44. Wang, X., Xu, X., Tao, W., Li, Y., Wang, Y., & Yang, L. (2012). A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease. *Evidence-Based Complementary and Alternative Medicine*, *2012*(1), 519031.
45. Gagnon, L. R., Sadasivan, C., Perera, K., & Oudit, G. Y. (2022). Cardiac complications of common drugs of abuse: pharmacology, toxicology, and management. *Canadian Journal of Cardiology*, *38*(9), 1331-1341.
46. Cazzola, M., Page, C. P., Calzetta, L., & Matera, M. G. (2012). Pharmacology and therapeutics of bronchodilators. *Pharmacological Reviews*, *64*(3), 450-504.
47. Foster, R. W. (Ed.). (2015). *Basic pharmacology*. Elsevier.
48. Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999). Pharmacological agents acting at subtypes of metabotropic glutamate receptors. *Neuropharmacology*, *38*(10), 1431-1476.
49. Li, T., Yuan, D., & Yuan, J. (2020). Antithrombotic drugs—pharmacology and perspectives. *Coronary artery disease: Therapeutics and drug discovery*, 101-131.
50. Griffin, C. E., Kaye, A. M., Bueno, F. R., & Kaye, A. D. (2013). Benzodiazepine pharmacology and central nervous system–mediated effects. *Ochsner Journal*, *13*(2), 214-223.
51. Becker, D. E. (2012). Basic and clinical pharmacology of autonomic drugs. *Anesthesia Progress*, *59*(4), 159-169.
52. Singh, S. (2007). *Pharmacology for dentistry*. New Age International.

ISBN: 978-81-985724-4-8

53. Townsend, J. F., & Luckey, T. D. (1960). Hormoligosis in pharmacology. *Journal of the American Medical Association*, *173*(1), 44-48.
54. Högestätt, E. D., & Zygmunt, P. M. (2002). Cardiovascular pharmacology of anandamide. *Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA)*, *66*(2-3), 343-351.
55. Tripathi, K. D. (2018). *Essentials of medical pharmacology*. Jaypee Brothers medical publishers.
56. Johnston, C. I. (1990). Biochemistry and pharmacology of the renin-angiotensin system. *Drugs*, *39*(Suppl 1), 21-31.
57. Riviere, J. E., & Papich, M. G. (Eds.). (2018). *Veterinary pharmacology and therapeutics*. John Wiley & Sons.
58. Sharma, A. M. (2005). Does pharmacologically induced weight loss improve cardiovascular outcome? Sibutramine pharmacology and the cardiovascular system. *European heart journal supplements*, *7*(suppl_L), L39-L43.
59. Lauven, P. M. (1990). Pharmacology of drugs for conscious sedation. *Scandinavian Journal of Gastroenterology*, *25*(sup179), 1-6.
60. Offermanns, S., & Rosenthal, W. (Eds.). (2021). *Encyclopedia of molecular pharmacology*. Cham: Springer International Publishing.
61. Satoskar, R. S., & Bhandarkar, S. D. (2020). *Pharmacology and pharmacotherapeutics*. Elsevier India.
62. Struijker-Boudier, H. A., Smits, J. F., & De Mey, J. G. (1995). Pharmacology of cardiac and vascular remodeling. *Annual Review of Pharmacology and Toxicology*, *35*, 509-539.
63. Leone, S., Di Cianni, S., Casati, A., & Fanelli, G. (2008). Pharmacology, toxicology, and clinical use of new long acting local anesthetics, ropivacaine and levobupivacaine. *Acta Biomed*, *79*(2), 92-105.
64. Christiaans, J. A. M., & Timmerman, H. (1996). Cardiovascular hybrid drugs: combination of more than one pharmacological property in one single molecule. *European journal of pharmaceutical sciences*, *4*(1), 1-22.
65. Rosano, G. M., & Panina, G. (1999). Cardiovascular pharmacology of hormone replacement therapy. *Drugs & aging*, *15*, 219-234.
66. Baruscotti, M., Bucchi, A., & DiFrancesco, D. (2005). Physiology and pharmacology of the cardiac pacemaker ("funny") current. *Pharmacology & therapeutics*, *107*(1), 59-79.

ISBN: 978-81-985724-4-8

67. Rawlins, M. D. (1981). Clinical pharmacology. Adverse reactions to drugs. *British medical journal (Clinical research ed.)*, *282*(6268), 974.
68. Sankaralingam, S., Kim, R. B., & Padwal, R. S. (2015). The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control. *Canadian Journal of Cardiology*, *31*(2), 167-176.
69. Wang, Y., Liu, Z., Li, C., Li, D., Ouyang, Y., Yu, J., ... & Wang, W. (2012). Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of qishenkeli acting on the coronary heart disease. *Evidence-based Complementary and Alternative Medicine*, *2012*(1), 698531.
70. Neal, M. J. (2020). *Medical pharmacology at a glance*. John Wiley & Sons.
71. VESTAL, R. F. (1982). Pharmacology and aging. *Journal of the American Geriatrics Society*, *30*(3), 191-200.
72. Hsu, W. H. (Ed.). (2013). *Handbook of veterinary pharmacology*. John Wiley & Sons.
73. Turner, R. (2013). *Screening methods in pharmacology*. Elsevier.
74. Spampinato, S. F., Sortino, M. A., & Salomone, S. (2022). Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: Pharmacology and clinical implications. In *Advances in Pharmacology* (Vol. 94, pp. 95-139). Academic Press.
75. Mauvais-Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., ... & Rubin, J. B. (2021). Sex-and gender-based pharmacological response to drugs. *Pharmacological reviews*, *73*(2), 730-762.
76. Amrein, R., & Hetzel, W. (1991). Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil. *Intensive care medicine*, *17*, S1-S10.
77. Bousquet, P., & Feldman, J. (1999). Drugs acting on imidazoline receptors: a review of their pharmacology, their use in blood pressure control and their potential interest in cardioprotection. *Drugs*, *58*(5), 799-812.
78. Oertelt-Prigione, S., & Regitz-Zagrosek, V. (2009). Gender aspects in cardiovascular pharmacology. *Journal of cardiovascular translational research*, *2*, 258-266.
79. Tashjian, A. H., & Armstrong, E. J. (2011). *Principles of pharmacology: the pathophysiologic basis of drug therapy*. Lippincott Williams & Wilkins.
80. Malloy, M. J., & Kane, J. P. (2007). Basic and clinical pharmacology.
81. Katzung, B. G. (2001). Introduction to autonomic pharmacology. *Basic and clinical pharmacology*, *13*, 87-109.

ISBN: 978-81-985724-4-8

82. Barkin, R. L. (2013). The pharmacology of topical analgesics. *Postgraduate medicine*, *125*(sup1), 7-18.
83. MacDonald, E., & Scheinin, M. (1995). Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system. *Journal of Physiology and Pharmacology*, *46*(3).
84. Ruffolo Jr, R. R. (1987). The pharmacology of dobutamine. *The American journal of the medical sciences*, *294*(4), 244-248.
85. Vaidya, A. D. (1997). The status and scope of Indian medicinal plants acting on central nervous system. *Indian journal of pharmacology*, *29*(5), 340-343.
86. Van Zwieten, P. A., Thoolen, M. J. M. C., & Timmermans, P. B. M. W. M. (1983). The pharmacology of centrally acting antihypertensive drugs. *British Journal of Clinical Pharmacology*, *15*(Supplement s4), 455S-462S.
87. Sinha, A. D., & Agarwal, R. (2019). Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. *Clinical Journal of the American Society of Nephrology*, *14*(5), 757-764.
88. Stanley, W. C., & Marzilli, M. (2003). Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. *Fundamental & clinical pharmacology*, *17*(2), 133-145.
89. de Groat, W. C., & Yoshimura, N. (2001). Pharmacology of the lower urinary tract. *Annual review of pharmacology and toxicology*, *41*(1), 691-721.
90. Andersson, K. E., & Wein, A. J. (2004). Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. *Pharmacological reviews*, *56*(4), 581-631.
91. Andersson, K. E., & Gratzke, C. (2008). Pharmacology of the lower urinary tract. *Textbook of the neurogenic bladder*, 95-114.
92. Caine, M. (Ed.). (2012). *The pharmacology of the urinary tract*. Springer Science & Business Media.
93. Andersson, K. E., & Hedlund, P. (2002). Pharmacologic perspective on the physiology of the lower urinary tract. *Urology*, *60*(5), 13-20.
94. Lose, G., & Thorup Andersen, J. (1986). Clinical pharmacology of the lower urinary tract. *European urology*, *12*(1), 1-11.
95. Fry, C. H. (2013). The physiology and pharmacology of the urinary tract. *Surgery (Oxford)*, *31*(7), 329-336.

ISBN: 978-81-985724-4-8

96. Andersson, K. E. (1999). Advances in the pharmacological control of the bladder. *Experimental physiology*, *84*(1), 195-213.
97. Fry, C. (2008). Pharmacology of the urinary tract. *Surgery (Oxford)*, *26*(4), 141-144.
98. Bradley, W. E., & Sundin, T. (1982). The physiology and pharmacology of urinary tract dysfunction. *Clinical Neuropharmacology*, *5*(2), 131-158.
99. Andersson, K. E. (2016). Potential future pharmacological treatment of bladder dysfunction. *Basic & clinical pharmacology & toxicology*, *119*, 75-85.
100. Jackson, E. K. (2018). Drugs affecting renal excretory function. *Goodman & Gilman's the Pharmacological Basis of Therapeutics. 13th ed. McGraw Hill*, 445-470.

ISBN: 978-81-985724-4-8